Stanozolol, sold under many brand names, is a synthetic androgen and anabolic steroid medication derived from dihydrotestosterone. It is used to treat hereditary angioedema. Technically, stanozolol is a 17-alpha-alkylated anabolic steroid with the empirical formula C21H32N2O and a molecular weight of approximately 328.49 g/mol. The 17-alpha alkyl group increases oral bioavailability by reducing first pass hepatic inactivation but also contributes to hepatotoxic potential. Stanozolol binds the androgen receptor, producing anabolic effects in skeletal muscle with limited aromatization to estrogen, and is primarily metabolized hepatically via oxidation and conjugation pathways with urinary excretion of polar metabolites. Typical physicochemical properties include low aqueous solubility, solid crystalline form for the active pharmaceutical ingredient, characteristic IR and NMR spectra for identity confirmation, and stability considerations under heat and oxidative conditions. Standard analytical control for the API uses HPLC-UV and LC-MS for assay and related substance profiling, NMR for structural confirmation, GC for volatile residual solvents, and ICP-MS for elemental impurities.
Parent: Stanozolol
Parent: Stanozolol
Pharmaceutical-grade stanozolol is typically manufactured and released with an assay greater than 98.0 percent by validated HPLC methods. Process-related impurities and related compounds commonly monitored include hydroxylated metabolites, reduced or oxidized ring products, positional isomers and diastereomers derived from the pyrazole and steroid rings, N-oxide species, and residual reagents or solvents from synthesis. Typical internal specification limits used by manufacturers are individual related compounds not greater than 0.5 percent area by HPLC and total unspecified impurities controlled below 1.5 percent area, with specified known impurities held to lower limits. Genotoxic or potentially mutagenic impurities are controlled to trace levels consistent with ICH thresholds and qualification requirements. Analytical control strategies include forced-degradation studies, qualification of impurities by LC-MS and NMR, residual solvent quantification by GC, water content by Karl Fischer titration, and elemental impurity assessment by ICP-MS to meet ICH Q3A, Q3B, Q3C and Q3D style expectations.
Stanozolol does not increase final adult height. In adolescents with open growth plates, exposure to androgens can accelerate bone maturation and lead to earlier epiphyseal closure, which may reduce final height. Stanozolol is not indicated as a growth-promoting agent and use during development carries the risk of impairing longitudinal growth.
No. Testosterone is the endogenous primary male sex hormone while stanozolol is a synthetic 17-alpha-alkylated derivative of dihydrotestosterone. Both activate the androgen receptor but differ in chemical structure, metabolic pathways, androgenic versus anabolic balance, oral bioavailability, and capacity to aromatize to estrogen. Their clinical profiles and safety considerations are therefore not equivalent.
Stanozolol can influence the central nervous system through androgen receptor modulation and downstream effects on neurotransmitter systems. Reported neuropsychiatric effects include changes in mood, irritability, aggression, altered libido, and sleep disturbances. Chronic or high-dose exposure has been associated with mood disorders and cognitive effects in some individuals. Mechanisms may involve interactions with dopaminergic, serotonergic and GABAergic signaling, but clinical outcomes vary by dose, duration and individual susceptibility.
Yes. Stanozolol and other 17-alpha-alkylated anabolic steroids commonly produce adverse changes in lipid profiles, typically reducing high density lipoprotein cholesterol and increasing low density lipoprotein cholesterol, which can raise cardiovascular risk. The magnitude of effect depends on dose and duration, and lipid monitoring is recommended when these agents are used clinically.
